MDG1.F -24.28% Medigene AG (XETRA) intraday 05 Feb 2026: liquidation risks ahead

MDG1.F stock dropped sharply 24.28% intraday on 05 Feb 2026, trading at EUR 0.0418 on XETRA as liquidity dried up and the company’s liquidation status weighed on buyers. Volume was just 200 shares versus an average of 13,649, magnifying price moves. The fall follows a small open at EUR 0.0396 and a prior close of EUR 0.0552, leaving the share price near its year low. Traders should treat intraday moves in Medigene AG with caution because low float, small market cap and ongoing liquidation can produce outsized swings.

MDG1.F stock: Intraday price action

Medigene AG (MDG1.F) slid EUR 0.0134 or 24.28% to EUR 0.0418 on XETRA during this intraday session. The stock’s day low was EUR 0.0396 and the day high was EUR 0.0418. Volume was 200 versus an avgVolume 13,649, giving a relative volume of 0.05, so price moves reflect thin trading.

Short-term momentum metrics show a 1-day move of -27.17% and a 3-month change of -27.44%, indicating recent weakness. Traders should expect large bid-ask spreads and execution risk in intraday trading of this ticker.

Why Medigene AG (MDG1.F) fell today

The immediate driver is market reaction to Medigene’s ongoing liquidation of remaining assets and virtually no operational pipeline news. The company description confirms a wind-down and the market is pricing exit uncertainty. With a market cap of EUR 592,451 and 14,737,594 shares outstanding, even small sell orders move the price materially.

Sector context matters: healthcare peers trade with much higher liquidity and average P/E ratios near 37.17 for large German sectors, while Medigene’s low float and liquidation status place it outside normal sector comparators.

MDG1.F analysis: fundamentals and valuation

Medigene AG reports an EPS of -1.67 and a negative P/E of -0.02, reflecting persistent losses. Key per-share metrics include cash per share EUR 1.2893 and book value per share EUR 1.6289, while the share price sits at EUR 0.0418, implying a deep disconnect between accounting book value and market price.

Meyka AI rates MDG1.F with a score of 58.43 out of 100 | Grade: C+ | Suggestion: HOLD. This grade factors in S&P 500 and sector comparisons, financial growth, key metrics and analyst consensus. This grade is informational and not investment advice.

Technicals, liquidity and trading risks

Price averages are weak: 50-day average EUR 0.0358 and 200-day average EUR 0.0720. The one-year high was EUR 1.804 and the low EUR 0.0192, showing extremely high historical volatility in percentage terms. Market structure is a risk: low daily volumes and a tiny market cap raise execution and liquidity risk.

Technical support zones to watch are near the year low EUR 0.0192 and a short-term support at EUR 0.0300; resistance appears around EUR 0.0500. Stop-loss discipline and limit orders are essential for intraday traders.

Outlook and Meyka AI forecast

Meyka AI’s forecast model projects a conservative 12-month target of EUR 0.03. Compared with the current price of EUR 0.0418, that implies an expected downside of -28.23%. An alternate liquidation-floor scenario near EUR 0.02 implies downside of -52.15%. Forecasts are model-based projections and not guarantees.

Catalysts that could alter the outlook include formal liquidation updates, asset sale announcements, or unusual volume spikes. Until clearer news arrives, expect continued volatility and thin trading.

Key catalysts and what traders should watch

Monitor the scheduled earnings/announcement date 26 Mar 2026 for any liquidation progress or cash distribution details. News on asset sales, creditor settlements or corporate filings will move the stock more than routine sector news.

Primary sources for company filings and updates are the corporate site and regulatory releases. For company background see Medigene’s site source and the public profile image/data snapshot source.

Final Thoughts

Key takeaways: MDG1.F stock plunged 24.28% intraday to EUR 0.0418 on XETRA on 05 Feb 2026 amid thin liquidity and ongoing liquidation of assets. Fundamentals show an EPS of -1.67, negative P/E and a tiny market cap of EUR 592,451, while balance-sheet metrics list cash per share EUR 1.2893 and book value per share EUR 1.6289. Meyka AI’s forecast model projects a conservative 12-month target of EUR 0.03, implying -28.23% versus the current price; a liquidation-floor scenario near EUR 0.02 implies -52.15%. Meyka AI rates MDG1.F with a score of 58.43/100 (C+, HOLD), reflecting weak trading liquidity, sector divergence and limited upside absent clear asset-sale news. For intraday traders the combination of low volume, wide spreads and corporate wind-down means heightened execution risk. Watch the 26 Mar 2026 announcement and any formal liquidation reports for the next decisive moves. Forecasts are model-based projections and not guarantees.

FAQs

Disclaimer:

Stock markets involve risks. This content is for informational purposes only. Past performance does not guarantee future results. Meyka AI PTY LTD provides market analysis and data insights, not financial advice. Always conduct your own research and consider consulting a licensed financial advisor.